In a phase 1 study looking at HER3-DXd in metastatic EGFR-mutated NSCLC with prior EGFR TKI therapy, 57 patients received the dose-recommended HER3-DXd of 5.6 mg/kg q3 weeks (44). This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.